[Radiotherapy of rectal carcinoma].
Approximately 2% of the Swiss population will develop rectal carcinoma during their lifetime. Most important prognostic factors are TNM category and quality of the surgical procedure. In advanced rectal carcinoma postoperative combined radio-chemotherapy reduces the rate of local recurrence by at least 50 percent and leads to a survival benefit of ca. 10-20%. However, preoperative radiotherapy (+/- chemotherapy) should be the treatment of choice as an adjunct to surgery, especially in cases of deep seated or fixed carcinomas. Intraoperative RT represents a promising modality in situations where a histologically complete excision of the tumor seems impossible.
Curschmann
J
J
Klinik für Radio-Onkologie mit Abteilung für Medizinische Strahlenphysik, Universität Bern, Inselspital.
Greiner
R H
RH
D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D015996:Survival Rate